Skip to main content
PATIENT PRESENTATION MARKER 

Eating-related risk 

What this marker measures

Presence/absence of eating-related risk that warrants further evaluation according to SCOFF questionnaire. It does not relate to food allergies or food safety-related risks. 

Health categories/Interpretations informed by this marker

‍
Clinical features
‍
‍● Psychosocial concerns: eating-related risk is a commonly-reported psychosocial factor that can affect quality of life. Disordered eating and GI symptoms may be bidirectionally associated. Disordered eating may predict incident IBS, and GI symptom severity may drive avoidant/restrictive eating.1,2
‍

Interpreting the result

PRESENT
Questionnaire responses give 'yes' to two or more SCOFF questions, flagging eating-related risk that warrants further evaluation by an appropriately trained health professional. 
NOT PRESENT
Questionnaire responses give 'yes' to fewer than two SCOFF questions. 

Patient management insights

clinical management
Refer to psychologist or medical practitioner: disordered eating and GI symptoms may be bidirectionally associated. Disordered eating may predict incident IBS, and GI symptom severity may drive avoidant/restrictive eating.1,2
GRADE C

Tips for patients discussion

"Your questionnaire responses suggest that food and eating may be causing you some stress or worry. This is more common than many people realise, and it can be linked with gut symptoms. Talking with someone who specialises in this can really help, and we can work out the right support together." 

Source references for all clinical associations, interpretation definitions, and patient management insights on this card.

1. Yang, K. et al. Maladaptive weight control and eating behaviours in female adolescents/young adults are associated with increased risk of irritable bowel syndrome in adulthood: results from the Growing Up Today Study (GUTS). Aliment Pharmacol Ther 60, 934–939 (2024). 
2. Almeida, M. N. et al. Gastrointestinal diagnoses in patients with eating disorders: a retrospective cohort study 2010–2020. Neurogastroenterol Motil 36, e14782 (2024).

© Copyright 2025 Microba Life Sciences
THESE PRODUCTS ARE ONLY AVAILABLE FOR PURCHASE THROUGH A HEALTHCARE PROFESSIONAL.
1. The quantitative faecal occult blood, polymerase chain reaction (qPCR) and enzyme-linked immunosorbent assays (ELISA) used in the Microbiome Explorer range are diagnostic and are approved for clinical use.
2. The faeces pH assay used in the Microbiome Explorer range is for research use only and not to be used as a basis for diagnosis. The metagenomic assays used in the Microbiome Explorer range are to determine the microbiome populations and associated functional pathways in a faecal sample. The application is for research use only and not to be used as a basis for diagnosis. Learn more about the journey we are on to validate this gold-standard technology for clinical diagnosis and application.
3. The Microbiome Explorer range is intended for adults 18 years or older only.

Disclaimer:
The information provided on this site is for the use of qualified healthcare professionals. The information contained on this website is in no way to be taken as prescriptive or to replace the healthcare professional's duty of care and personalised care practices.